Felbamate ' s chemical structure
Find information on thousands of medical conditions and prescription drugs.

Felbatol

Felbamate (marketed as Felbamol by MedPointe) is an anticonvulsant drug used in the treatment of epilepsy. It is used to treat partial seizures (with and without generalization) in adults and partial and generalized seizures associated with Lennox-Gastaut syndrome in children. However, an increased risk of potentially fatal aplastic anemia and/or liver failure limit the drugs usage to severe refractory epilepsy. more...

Home
Diseases
Medicines
A
B
C
D
E
F
Captagon
Famohexal
Famotidine
Faslodex
Faslodex
Fasoracetam
Felbamate
Felbatol
Felodipine
Felypressin
Femara
Femara
Fempatch
Femring
Fenfluramine
Fenofibrate
Fentanyl
Fexofenadine
Filgrastim
Filipin
Finasteride
Fioricet
Fiorinal
Flagyl
Flarex
Flavoxate
Flecainide
Flexeril
Flomax
Flonase
Flovent
Floxuridine
Fluacizine
Flucloxacillin
Fluconazole
Flucytosine
Fludarabine
Fludrocortisone
Flumazenil
Flunisolide
Flunitrazepam
Fluocinonide
Fluohexal
Fluorometholone
Fluorouracil
Fluoxetine
Fluphenazine
Flurazepam
Flutamide
Fluticasone
Fluvastatin
Fluvoxamine
FML
Focalin
Folic acid
Follutein
Fomepizole
Formoterol
Fortamet
Fortovase
Fosamax
Fosinopril
Fosinoprilat
Fosmidomycin
Fosphenytoin
Frova
Frovatriptan
Frusehexal
Fulvestrant
Fumagillin
Furazolidone
Furosemide
Furoxone
Fusafungine
Fusidic acid
Fuzeon
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Mechanism of Action

As with most anticonvulsants, the precise mechanism is unknown. It has a weak inhibitory effect on GABA receptor binding sites.

Approval History

U.S.

  • August 1993. Felbamate was approved for partial seizures with and without secondary generalization in adults and for Lennox-Gastaut Syndrome, a serious form of childhood epilepsy. Over the following year 150,000 people were started on felbamate therapy and a third of these became established.
  • August 1st 1994. It was urgently withdrawn after 10 cases of aplastic anemia. A "Dear Doctor" letter was sent to 240,000 physicians.
  • September 27th 1994. Felbamate had a limited redemption in another "Dear Doctor" letter sent to 260,000 physicians. It was recommended that the drug remain available only for patients with severe epilepsy for whom the benefits outweigh the risks, and that changes be made to the product's labelling to reflect the newly recognized risk . This redemption came with an additional warning since there had been 10 cases acute liver failure (4 of which were fatal). At this point, 10,000 to 12,000 people remained on the drug.

U.K.

  • The drug is only available on a limited named-patient basis.

Indications & Usage

  • Adults: Monotherapy or adjunctive therapy in the treatment of partial seizures, with and without generalization.
  • Children: Adjunctive therapy in the treatment of partial and generalized seizures associated with Lennox-Gastaut syndrome.

Dosing

Felbamate is available in tablets (400 mg and 600 mg) and as a peach-coloured oral suspension (600 mg/5 mL).

  • Adults (> 14 years): begin with 1,200 mg daily given every 6 to 8 hours
  • Children (2 > 14 years): 15 to 45 mg per kg per day given every 6 to 8 hours

Side Effects

Adverse reactions include decreased appetite, vomiting, insomnia, nausea, dizziness, somnolence, and headache. Many patients report increased alertness with the drug. Two rare but very serious effects include aplastic anemia and hepatic (liver) failure. The risk of aplastic anemia is between 1:3,600 and 1:5,000, of which 30% of cases are fatal. The risk of hepatic failure is between 1:24,000 to 1:34,000.

Drug Interactions

Felbamate interacts with other AEDs, the dose of which may be reduced in order to avoid adverse effects.

Read more at Wikipedia.org


[List your site here Free!]


Drug- And Herb-Induced Liver Failure: A Rare Adverse Reaction To A Wide Range Of Drugs - Brief Article
From Healthfacts, 9/1/01 by Maryann Napoli

In the last few years, several widely promoted drugs have been removed from the market because of rare and severe liver toxicity. For example, Rezulin, a drug for type 2 diabetes, was withdrawn last year after it was found to have caused 90 cases of liver failure, including 63 deaths. A rare side effect usually does not become evident until a few years after the drug is on the market and hundreds of thousands of people have taken it; whereas, the premarket testing required by the Food and Drug Administration (FDA) usually involves, at best, a few thousand study participants. Finding a rare drug side effect is complicated further by the fact that fewer than 10% of all adverse drug reactions are reported to the FDA.

Serious drug-induced liver injury is now the leading cause of removal of a drug from the market. The liver damage usually occurs with little or no advance warning, though in the case of Rezulin, signs of drug-induced toxicity in the premarket testing phase were ignored because they were not severe enough. A rare side effect can affect a large number of people once you consider that the risk is associated with a wide range of commonly used prescription and non-prescription drugs, as well as herbal products. Over 1,000 people in the U.S. die yearly of drug- induced liver failure. Many more are hospitalized, and some require a liver transplant.

To find ways of averting such tragedies, a conference was held early this year, called "Drug-Induced Liver Injury: A National and Global Problem," sponsored by the FDA, the Pharmaceutical Research and Manufacturers of America, and academic consultants from the American Association for the Study of Liver Diseases. The abstracts and background papers from this conference have been made available on the FDA's Web site (www.FDA.gov/cder).

Emphasis was largely upon how to test for and identify early signs of liver toxicity during the premarket testing phase. Addressing the conference, the FDA's Robert Temple, MD, said, "Post-marketing surveillance now detects serious hepatotoxins in months, in marked contrast to the years of delay of the past, but it's obviously preferable to discover them before marketing."

The FDA is searching for ways to reduce injuries associated with acetaminophen (Tylenol), a drug whose well-documented risk of liver damage is entirely predictable. Damage severe enough to cause death or require a liver transplant will occur in people who intentionally, or accidentally, take acetaminophen in higher than recommended doses (no more than 1,200 mg/day), especially when associated with alcohol. People who regularly drink three or more alcoholic drinks daily and those who have not eaten for a long period of time are most likely to suffer acetaminophen- induced liver damage.

The FDA takes different avenues of public protection once a drug is known to be a rare cause of liver injury. The agency can withdraw the drug (e.g., Oraflex), mandate a warning box on the label (e.g., acetaminophen), or severely restrict usage (e.g., the antibiotic, Trovan).

Other Drugs That Can Damage the Liver:

This is a partial list of drugs and herbs that can, though rarely, cause liver injury. It was compiled by the FDA Center for Drug Evaluation and Research.

Niacin (nicotinic acid) for cholesterol-lowering;

Isoniazid (has a dozen other brand names: Laniazid, Nydrazid) for tuberculosis;

Normodyne (other brand names: Normozide [CD], Trandate), a beta- blocker for hypertension;

Cylert for attention deficit disorder;

Lamisil, Nizoral, Sporanox for fungal infections,

Felbatol for epilepsy;

Zyflo (other brand names: Montelukast, Singulair, Zafirlukast, Accolate, Zileuton) for asthma;

And Tasmar for Parkinson's disease.

Herbs that may cause liver damage include chaparral, comfrey, valerian, ma huang, and pennyroyal.

--

Maryann Napoli is the associate director of the Center for Medical Consumers in New York City.

COPYRIGHT 2001 Center for Medical Consumers, Inc.
COPYRIGHT 2001 Gale Group

Return to Felbatol
Home Contact Resources Exchange Links ebay